IL33 and psoriasis: After release, IL-33 can diffuse from the epidermis into the dermis, triggering ST2-positive cells, including MCs, since the gene expression levels of IL-33 and histidine decarboxylase are significantly increased in the skin of patients with psoriasis (72, 73).